Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts October 28, 2013 Genzyme, a Sanofi company, is pleased to update the Niemann-Pick disease patient community on the progress of efforts to - Sphingomyelin phosphodiesterase 1 - Document - PDFSEARCH.IO

First Page	Meta Content
	Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts October 28, 2013 Genzyme, a Sanofi company, is pleased to update the Niemann-Pick disease patient community on the progress of efforts to Add to Reading List Document Date: 2013-10-25 15:19:52 Open Document File Size: 275,95 KB Share Result on Facebook City New York / Cambridge / Framingham / / Company Genzyme Corporation / Sanofi company / / Country Germany / United Kingdom / France / United States / Chile / Brazil / Italy / / Event FDA Phase / / Facility Mary’s Hospital / / / IndustryTerm infused protein-based product / / MedicalCondition Niemann-Pick disease Type B. We / B disease / Acid Sphingomyelinase Deficiency / Niemann-Pick disease / non-neurological manifestations / / MedicalTreatment enzyme replacement therapy / / NaturalFeature Mount Sinai / / Organization St. Mary’s Hospital in Manchester / / / Product Niemann-Pick Type B / Q1 / / ProvinceOrState Massachusetts / / URL www.genzyme.com / / SocialTag Biology Niemann–Pick disease Medicine Sphingomyelin Genzyme Clinical trial Sphingomyelin phosphodiesterase 1 Niemann-Pick disease, type C Health Lipid storage disorders

Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts October 28, 2013 Genzyme, a Sanofi company, is pleased to update the Niemann-Pick disease patient community on the progress of efforts toAdd to Reading List